Affiliation:
1. The University of Melbourne
2. St. Vincent's Hospital Melbourne, Melbourne, Victoria
3. The University of Sydney School of Public Health, Sydney
4. Royal Prince Alfred Hospital Sydney
5. SydneyMSK Research Flagship Centre, University of Sydney, Sydney, New South Wales, Australia
Abstract
Purpose of review
Systemic sclerosis (SSc)-associated heart involvement (SHI) is a significant cause of both morbidity and mortality in individuals with SSc. SHI can take many different forms, and likely is a spectrum of fibroinflammatory cardiac disease. Presenting features include arrhythmia, ventricular systolic or diastolic dysfunction, pericardial disease, and exercise intolerance. Risk of sudden cardiac death in SSc is likely 10–30-fold greater than general population estimates. In this review, we explore what is known about the pathogenesis of SHI, its prevention and management, and discuss available strategies for screening for SHI in light of new recommendations for the routine screening of SHI in all SSc patients.
Recent findings
We describe the spectrum, clinical features, and pathogenesis of SHI. Furthermore, we review the new recommendations for screening for SHI in individuals with SSc.
Summary
There is a large, under-recognized burden of SHI in people living with SSc, which likely contributes to the significant increase in sudden cardiac death observed in SSc. However, a broad-based screening approach, including asymptomatic, low-risk patients should be viewed with caution given the lack of evidence-based treatments and interventions for SHI particularly in this group.
Publisher
Ovid Technologies (Wolters Kluwer Health)